Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsRobert Joseph Stagg, Steven Eugene Benner
Life of this patent
Estimating the term…
Abstract
Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
Claims27
1-51. (canceled)
A method of treating cancer comprising:
- a) administering a DLL4 antagonist to a subject in need of treatment, wherein the DLL4 antagonist is an antibody that specifically binds human DLL4;
- b) measuring the blood pressure of the subject after receiving treatment with the DLL4 antagonist;
- and
- c) administering to the subject a therapeutically effective amount of one or more antihypertensive agents to control hypertension caused by the DLL4 antagonist.
A method of monitoring a subject for the development of hypertension caused by a DLL4 antagonist, wherein the DLL4 antagonist is an antibody that specifically binds human DLL4, the method comprising:
- a) administering a DLL4 antagonist to a subject in need of treatment;
- b) measuring the blood pressure of the subject after receiving treatment with the DLL4 antagonist;
- and
- c) administering to the subject a therapeutically effective amount of one or more antihypertensive agents to control hypertension caused by the DLL4 antagonist.
A pharmaceutical composition comprising a DLL4 antagonist and one or more anti-hypertensive agents, wherein the DLL4 antagonist is an antibody that specifically binds human DLL4.
Dependencies are inferred from the claim text.